Pharma News

The NIHR-funded and supported study RECOVERY (Randomised Evaluation of COVid-19 thERapY) has today announced that the steroid dexamethasone has been identified as the first drug to improve survival rates in certain coronavirus patients.

Dr. Reddy's Laboratories has entered into a non-exclusive Licensing Agreement with Gilead Sciences that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Sun Pharma's wholly-owned subsidiaries and Hikma Pharmaceuticals PLC (Hikma) have entered into an exclusive licensing and distribution agreement for ILUMYA™, an innovative biologic product, for the Middle East & North Africa (MENA) region.

Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is now expected to commence in the second half of July.

Schematic of the main protease of SARS CoV-2 (left), the protein residue network of the main protease of SARS CoV-2 (center), and a zoomed-in view of the region around the binding site as detected by Estrada (right). CREDIT: Ernesto Estrada

As the COVID-19 pandemic caused by the coronavirus SARS-CoV-2 continues to spread around the world, many researchers are studying epidemiological models to predict its propagation.

In the current pandemic scenario, global supplies of nasopharyngeal (NP) swabs are not dependable resulting in supply chain delays, escalating prices and variable quality. CSIR-National Chemical Laboratory (CSIR-NCL), Pune, has developed an indigenous NP swab for collecting samples from the throat cavity of COVID-19 patients. The need for making available domestic technology for NP swabs was flagged by CSIR to NCL in mid-April.

Researchers from the Indian Institute of Integrative Medicine (IIIM), Jammu, have identified a potent compound that has shown cancer-inhibiting activity in their primary studies on pancreatic cancer. For this compound, they have received Investigational New Drug (IND) approval from the New Drugs Division of the Central Drugs Standard Control Organization (CDSCO). It has been recognized as a potent anti-cancer, New Chemical Entity (NCE) effective against pancreatic cancer after completion of preclinical development and IND submission.

A team of researchers from IIT Madras, Cancer Institute, Sree Balaji Dental College and Hospital, Chennai, and Indian Institute of Science (IISc) Bengaluru have identified a specific microRNA (miRNAs) called ‘miR-155’ that is over-expressed in tongue cancer. MicroRNAs (miRNAs) are small Ribo Nucleic Acid. They are non-coding RNAs involved in the regulation of a variety of biological and pathological processes, including the formation and development of cancer. This finding is important in that molecular strategies can potentially be devised to manipulate miR-155 expression to develop therapeutics for tongue cancer.